Skip to main content
TipRanks
Go Ultimate75% OFF

Clinical Laserthermia Systems AB Class B (LS60) AI Stock Analysis

2 Followers
DE:LS60

Clinical Laserthermia Systems AB Class B

(Frankfurt:LS60)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-Free Balance SheetZero reported debt materially reduces refinancing pressure and interest-related financial risk while the company continues to operate at a loss. Positive equity provides a solvency buffer, giving management more flexibility to pursue commercialization and absorb operating volatility over the next several quarters.
Negative Factors
Declining RevenueRevenue contraction indicates that commercial demand or realized sales have not yet established a durable growth trajectory. Lower volume also makes it harder to absorb fixed operating costs, limiting the company’s ability to convert its platform and clinical technology into sustainable earnings.

Clinical Laserthermia Systems AB Class B (LS60) vs. iShares MSCI Germany ETF (EWG)

-100%-80%-60%-40%-20%0%20%DE:LS60-83.06%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 7.64M
Dividend Yield
―
Average Volume (3M)
2,500
Price to Earnings (P/E)
-1.3
Beta (1Y)
0.04
Revenue Growth
-45.99%
EPS Growth
41.88%
Country
Germany
Employees
13
Sector
Healthcare
Sector Strength
51
Industry
Medical - Specialties

Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model

Company Description

Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The...

Clinical Laserthermia Systems AB Class B Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:LS60 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CRAD.BSE:CRAD.B64NeutralSEK 820.54M17.6913.23%0.40%-8.76%103.87%
SE:RAY.BSE:RAY.B63NeutralSEK 6.03B29.7822.61%2.23%3.16%-5.78%
SE:PAXSE:PAX60NeutralSEK 1.45B-309.35-1.22%―34.05%-144.96%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:SPAGOSE:SPAGO42NeutralSEK 36.09M-1.13-87.37%―-97.52%31.31%
SE:SPECSE:SPEC42NeutralSEK 22.68M-0.11-57.15%――16.02%

* Healthcare Sector Average

Performance Comparison

-75%-50%-25%0%DE:LS60SE:PAXSE:RAY.BSE:SPECSE:CRAD.BSE:SPAGODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:LS60 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:LS60Clinical Laserthermia Systems AB Class B0.11-0.59-84.02%
SE:PAXPaxman AB67.506.9011.39%
SE:RAY.BRaySearch Laboratories AB Class B179.30-40.55-18.44%
SE:SPECSpectraCure AB0.01-0.12-90.08%
SE:CRAD.BC-Rad AB Class B24.90-9.69-28.02%
SE:SPAGOSpago Nanomedical AB0.04-0.07-61.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.